Kerberos Biopharma is an emerging Philadelphia based biotechnology company targeting late stage cancer. There is considerable evidence for the involvement of chemokines in cancer, both in tumor progression and metastatic dissemination of the disease. Kerberos is the world-leader in the research and development of highly potent small molecule antagonists of CX3CR1 and has identified and profiled an IND candidate with back-ups targeting Inflammatory Breast Cancer (IBC) as its first indication.

Kerberos founders have raised approximately $4.5M in CX3CR1 grants and research funding to date. Kerberos is actively fundraising to advance its lead program into clinical development for IBC, an orphan drug indication with potential breakthrough regulatory designation.